A few days ago, IVDWorker published an article “What? Tellgen’s Chairman Challenged to Assemble/Disassemble a Fully Automated CLIA Analyzer in 3 Minutes?” which went viral. The big highlight of this article was that the chairman of Tellgen successfully took up the challenge of assembling/disassembling an instrument in just 3 minutes on stage – an explosive performance
The instrument in question is Tellgen’s new compact CLIA product launched this year – the fully automated chemiluminescence immunoassay analyzer TESMI i50. For compact CLIA instruments, Tellgen defines them as having “small footprint, low maintenance, and low cost”.
I asked Chairman Yao at Tellgen why low maintenance and low cost are important for compact instruments, apart from the small size. He gave an example of Indonesia, a nation where hospitals are scattered across different small islands, making it difficult for engineers to reach them quickly. Additionally, with limited weekly sample volumes, reducing instrument and reagent costs is crucial for sustainable development. Even in the domestic market, as compact CLIA instruments penetrate deeper into community hospitals, effective after-sales service becomes increasingly important. Therefore, these instruments need to be not only compact but also low-maintenance and low-cost.
This is the solution that Tellgen is providing to the industry. But how many test items can the TESMI i50 handle? Tellgen says that with acridinium ester chemiluminescence technology, it can run at least 70 test items!
Tellgen demonstrates two kinds of involution – one for its products, and one for its chairman!
In terms of involution of products, the TESMI i50 is designed to be extremely compact, reducing its footprint to two-thirds of comparable instruments. Its modular design allows regular engineers to replace components after simple training. The reagents are packaged in small sizes, leading to significant cost reductions!
When it comes to a dedicated chairman, Tellgen doesn’t hold back either. To demonstrate the compact size, the chairman himself measured it by hand. To showcase low maintenance, he performed a 3-minute module replacement on stage. And when it came to pricing, the chairman asked the distributors to suggest a suitable price themselves, saying that the more they buy, the bigger the discount would be – a true sales pitch!
The company’s second major announcement was the launch of its third-generation laboratory automation system, the TESCLAS T9. This represents an important milestone in Tellgen’s evolution of automation systems. As one of the earliest domestic companies to enter this field, Tellgen collaborated with Hitachi on a compatible automation system in 2018, becoming one of the pioneers of compatible systems in China. In 2021, amidst the rapid development of domestic automation systems, Tellgen gradually introduced its own systems, the TESLAS T6 and T8. And now, at the CACLP conference, Tellgen has unveiled its third-generation total laboratory sample prep for biochemistry and immunoassay automation system – the TECLAS T9.
From pioneering to transcendence, Tellgen has taken 6 years to develop an automation system better suited to the Chinese market. In terms of compatibility, it boasts comprehensive support for multiple imported and domestic automated biochemistry analyzers. Its independent auto QC module allows laboratories to perform automated quality control for different analyzers as per their requirements, giving them full control over timing.
Upon closer inspection, the TECLAS T9 also incorporates several cutting-edge technologies. It can process 500 samples per hour, significantly outperforming competitors in terms of space utilization. The centrifuge module uses a high-speed, low-noise motor core, ensuring noise levels below 60 decibels during daily use. The aluminum alloy track is an integrated die-casting, reducing weight by over 30%! It’s clear that the T9 has been extensively optimized based on market needs and customer usage scenarios, not only improving various manufacturing processes but also lowering production costs. In the current context of pricing pressure from centralized procurement in the biochemistry and immunoassay industry, this offers a more flexible choice.
Innovation and Strength Underpin Tellgen’s “Extreme Dedication”
Starting a few years ago, the IVD industry has been under constant pressure. There were concerns about whether it would remain a viable industry after the centralized procurement policies that impacted the pharmaceutical sector. This became a hot topic, with some companies considering leaving or avoiding entry into this field. However, IVD companies deeply rooted in the industry are actively seeking new breakthroughs and redefining their products and services.
Tellgen’s two kinds of “extreme dedication” stem from a customer-centric and market-centric approach of looking inward for answers. Products are the lifeblood of a company; only great products that meet customer needs can withstand market competition. The chairman is the helmsman guiding the company’s development. By immersing themselves in the industry and staying close to customers, they can steer the company towards a more prosperous future.
The courage to go to perfections with products, making them the best they can be, and the courage to seek for perfections with leadership, aligning the company’s development firmly with customer needs – this is the driving force behind a company’s growth, a manifestation of its strength and innovation.
Reprint from WeChat: IVDworker